复星医药(02196.HK)参投星曜坤泽 推进乙肝功能性治愈管线全球临床开发

阿斯达克财经
May 29

复星医药(02196.HK) 宣布,将通过控股子公司上海复星医药产业发展有限公司出资共计约4.14亿元人民币,参与星曜坤泽B轮融资及股权转让交易。本轮融资及股权转让总额超6.3亿元,交易全部完成后,复星医药预计将持有星曜坤泽约20.87%的股权,进一步深化在肝病治疗领域的战略布局。星曜坤泽本次募集资金预计将重点用于其核心产品的全球临床开发与注册申报、联合治疗策略的深度拓展、商业化及产业化能力的系统...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10